achiev
better
life
cystic
fibrosi
cf
patient
mainli
caus
better
manag
infect
control
last
three
decad
herein
want
summar
cornerston
effect
manag
cf
patient
give
overview
knowledg
fungal
epidemiolog
clinic
context
europ
data
retrospect
analysi
encompass
sampl
cf
patient
followedup
cf
center
differ
european
countri
shown
cystic
fibrosi
cf
one
common
autosom
recess
diseas
europ
dysfunct
epitheli
electrolyt
transport
caus
product
viscou
secret
exocrin
gland
due
viscou
mucu
cf
patient
airway
recurr
bacteri
infect
respiratori
tract
commonli
occur
play
crucial
role
progress
diseas
colon
lung
bacteria
predominantli
pseudomona
aeruginosa
thought
main
caus
morbid
mortal
cf
cours
cf
diseas
fungal
colon
airway
respiratori
infect
play
increas
role
especi
due
rise
awar
fungal
growth
microbiolog
diagnost
longer
life
expect
rise
percentag
immunocompromis
cf
patient
scope
studi
give
short
comprehens
overview
manag
cf
patient
synopsi
cornerston
diagnost
therapi
gener
second
part
elucid
publish
data
concern
fungal
epidemiolog
cf
context
europ
retrospect
analyz
fungal
epidemiolog
divers
cf
center
distribut
differ
european
countri
last
decad
cf
care
worldwid
specif
europ
evolv
mani
way
earli
diagnosi
neonat
screen
prolifer
across
europ
adult
popul
patient
steadili
increas
countri
numer
pass
pediatr
popul
new
treatment
avail
includ
mutationspecif
therapi
might
potenti
chang
natur
histori
diseas
emphasi
given
clinic
research
network
european
cf
center
establish
aim
facilit
highqual
clinic
trial
translat
new
therapi
clinic
care
epidemiolog
data
mani
european
countri
becom
avail
eurocarecf
project
nation
intern
registri
evid
dispar
alloc
resourc
clinic
outcom
also
emerg
landscap
cf
chang
dramat
futur
europ
data
obtain
european
cystic
fibrosi
societi
patient
registri
reveal
forecast
european
countri
one
side
promis
side
dramat
data
indic
number
cf
patient
increas
approxim
mainli
due
neonat
screen
program
moreov
number
cf
adult
increas
approxim
find
mostli
result
transit
children
adult
wherea
number
cf
children
show
increas
result
crucial
peopl
cf
complex
care
need
demand
specialist
medic
alli
healthcar
expertis
life
expect
increas
significantli
success
patient
birth
cohort
result
effect
treatment
crucial
patient
attend
cf
center
line
demonstr
patient
attend
cf
center
care
better
wellb
lung
function
manag
patient
mean
nowaday
implement
multidisciplinari
team
cf
center
adequ
resourc
eg
staf
comput
equip
infrastructur
inpati
outpati
facil
allow
multidisciplinari
team
provid
level
care
accord
european
cystic
fibrosi
societi
ecf
standard
recommend
cf
center
minimum
adult
pediatr
patient
warrant
enough
experi
appropri
level
expertis
cf
center
must
allow
access
center
emerg
care
h
day
week
routin
appoint
peopl
stabl
diseas
everi
month
also
depend
sever
diseas
newli
diagnos
infant
seen
frequent
initi
weekli
patient
annual
assess
ensur
high
qualiti
care
aim
prevent
progress
diseas
diagnos
new
cfrelat
diseas
diabet
osteoporosi
patient
treat
either
outpati
depart
ward
standard
oper
procedur
exist
prevent
crossinfect
patient
one
import
structur
patient
manag
access
special
diagnost
aforement
patient
cf
reach
higher
averag
lifetim
therefor
mandatori
reduc
risk
late
sequela
annual
radiolog
diagnost
perform
xray
comput
tomographi
ct
scan
produc
signific
amount
radiat
exposur
patient
newer
techniqu
magnet
reson
imag
mri
allow
compar
examin
lung
addit
radiolog
nuclear
medicin
servic
still
includ
ct
scan
liver
ultrasound
dualenergi
xray
absorptiometri
dxa
bone
scan
lung
function
measur
must
avail
outpati
depart
well
ward
cf
patient
gain
mobil
exercis
test
fitnesstofli
test
avail
term
chronic
lung
diseas
acquisit
sever
differ
microorgan
lifetim
microbiolog
servic
abil
process
sampl
peopl
cf
reliabl
detect
burkholderia
spp
nontubercul
mycobacteria
aspergillu
infect
well
rare
bacteria
fungi
molecular
pathogen
type
immunolog
allerg
bronchopulmonari
aspergillosi
abpa
monitor
also
implement
structur
cf
center
abpa
occur
cf
patient
aforement
multidisciplinari
team
key
good
qualiti
care
multiorgan
diseas
like
cf
therefor
everi
singl
specialist
packag
work
structur
includ
entir
concept
patient
care
long
list
team
member
medic
doctor
cf
nurs
physiotherapist
dietician
psychologist
play
import
role
build
core
team
special
knowledg
need
subgroup
team
team
need
facil
structur
standard
oper
procedur
sop
avail
yearli
checkup
addit
plan
visit
patient
cf
common
complic
diseas
need
addit
servic
medic
doctor
nurs
crucial
awar
complic
structur
sop
must
implement
cf
center
pneumothorax
hemoptysi
distal
intestin
obstruct
syndrom
hepatobiliari
complic
cfrelat
diabet
abpa
respiratori
insuffici
furthermor
physiotherapist
topic
regard
treatment
cf
lung
diseas
cf
physiotherapist
avail
regular
contact
assess
patient
treatment
lung
function
test
physic
surveil
therapi
evalu
frequenc
vari
accord
patient
age
clinic
statu
minimum
happen
everi
routin
outpati
clinic
daili
hospit
includ
patient
admit
care
specialist
intens
care
extens
assess
take
place
annual
major
issu
implement
cf
care
physiotherapist
airway
clearanc
therapi
inhal
therapi
exercis
capac
test
postur
musculoskelet
assess
noninvas
implement
team
member
psychologist
receiv
increas
number
problem
solv
one
major
part
context
mental
health
studi
quittner
et
al
psycholog
symptom
report
patient
cf
parent
elev
symptom
depress
found
adolesc
adult
mother
father
elev
anxieti
found
adolesc
adult
mother
father
overal
elev
time
commun
sampl
particip
report
elev
anxieti
like
report
depress
or
adolesc
adult
mother
father
result
show
strong
need
implement
screen
routin
set
cf
center
role
specialist
cf
dietician
take
lead
provid
highqual
treatment
care
ensur
optim
nutrit
statu
includ
nutrit
screen
surveil
regular
patient
assess
review
aspect
nutrit
gastrointestin
statu
frequenc
type
assess
vari
age
clinic
statu
term
cf
care
framework
microbiolog
special
interest
patient
suffer
chronic
acut
infect
due
high
number
differ
bacteria
fungi
clinic
microbiologist
particular
knowledg
cf
infect
part
cf
multidisciplinari
team
person
may
medic
train
clinic
microbiologist
infecti
diseas
specialist
clinic
scientist
relev
knowledg
experi
could
also
undertak
role
cf
clinic
microbiologist
work
close
microbiolog
laboratori
provid
diagnost
servic
member
cf
multidisciplinari
team
well
local
infect
control
prevent
team
provid
support
cf
multidisciplinari
team
diagnosi
treatment
infect
cf
clinic
microbiologist
need
know
rang
infect
colon
cf
particular
need
awar
role
unusu
microorgan
risk
crossinfect
impact
longterm
chronic
infect
microbiolog
laboratori
test
antiinfect
treatment
addit
good
basic
knowledg
cf
clinic
microbiologist
evid
continu
profession
develop
cf
microbiolog
regularli
attend
specialist
cf
meet
confer
cf
clinic
microbiologist
ensur
full
rang
microbiolog
laboratori
test
need
cf
center
avail
laboratori
servic
provid
base
current
publish
guidelin
laboratori
fulli
accredit
recogn
nation
scheme
clinic
microbiolog
particip
extern
qualiti
assur
program
includ
cfassoci
pathogen
provis
send
relev
sampl
refer
laboratori
special
cf
microbiolog
requir
laboratori
provid
accur
time
result
cf
center
agre
system
notifi
urgent
import
result
technic
staff
laboratori
suffici
expertis
knowledg
deal
complex
microbiolog
cf
infect
framework
record
investig
error
incid
evid
lesson
learn
use
inform
program
servic
improv
servic
regularli
audit
exampl
audit
turnaround
time
ie
time
receipt
sampl
laboratori
avail
result
cf
multidisciplinari
team
accuraci
identif
suscept
test
appropri
prompt
commun
urgent
result
cf
multidisciplinari
team
special
item
clear
multidisciplinari
team
microbiologist
regard
infect
patient
respiratori
sampl
taken
process
eg
sputum
bronchoalveolar
lavag
cough
swab
pharyng
swab
sampl
taken
diagnosi
infect
intravascular
line
diagnosi
infect
includ
infect
gut
eg
enter
virus
test
toxigen
clostridium
difficil
level
identif
microorgan
eg
genu
speci
subtyp
requir
individu
case
may
includ
discuss
test
perform
local
laboratori
may
need
refer
special
laboratori
advanc
test
methodolog
eg
confirm
first
infect
burkholderia
spp
accur
speci
identif
type
method
frequenc
type
ie
often
cf
multidisciplinari
team
send
sampl
routin
surveil
addit
type
done
due
suspicion
crossinfect
measur
antipseudomon
antibodi
appropri
provis
diagnost
test
fungal
mycobacteri
infect
togeth
level
identif
role
type
suscept
testingagr
antibiot
antifung
test
suscept
test
help
virolog
servic
includ
rapid
identif
highli
pathogen
virus
may
spread
patientsboth
familiar
eg
influenza
viru
emerg
viral
pathogen
eg
sever
acut
respiratori
syndromerel
coronaviru
middl
east
respiratori
syndromerel
coronaviru
result
need
phone
urgent
cf
multidisciplinari
team
eg
first
isol
pseudomona
aeruginosa
new
isol
burkholderia
cepacia
complex
burkholderia
speci
sputum
methicillinresist
staphylococcu
aureu
mycobacterium
speci
advic
infect
prevent
control
cf
clinic
microbiologist
work
close
togeth
member
cf
multidisciplinari
team
addit
local
infect
control
team
creat
consent
local
infect
control
prevent
polici
procedur
line
expert
nation
intern
guidelin
polici
includ
differ
strategi
tabl
last
year
fungal
colon
respiratori
tract
cf
patient
rais
attent
due
better
evalu
fungal
divers
cf
airway
awar
also
caus
increas
number
immunocompromis
cf
patient
eg
lung
transplant
often
fatal
outcom
case
invas
infect
rare
fungal
speci
aim
section
summar
publish
data
concern
fungal
epidemiolog
cf
europ
give
short
overview
spot
europ
furthermor
also
present
collect
data
differ
european
center
intent
sensit
clinician
microbiologist
issu
role
certain
fungal
speci
progress
lung
diseas
still
discuss
well
prophylact
use
antifung
therapi
lung
transplant
exclus
cf
patient
respiratori
tract
colon
specif
mold
yeast
mold
often
cultur
respiratori
tract
cf
patient
despit
colon
candida
speci
major
candida
albican
clinic
role
yeast
still
clarifi
concern
filament
fungi
aspergillu
fumigatu
highest
impact
cf
patient
respiratori
tract
cf
patient
colon
aspergillu
speci
cf
patient
suffer
abpa
local
infect
seen
cf
patient
abnorm
airway
like
aspergilloma
immunocompromis
sever
risk
invas
aspergillosi
scedosporium
lomentospora
speci
formerli
call
pseudallescheria
respons
numer
infect
immunocompromis
patient
healthi
individu
neardrown
accid
highresist
profil
fungi
antifung
agent
often
complic
therapeut
approach
colon
scedosporium
lomentospora
speci
shown
fatal
clinic
outcom
lung
transplant
case
exophiala
dermatitidi
cultiv
respiratori
specimen
cf
patient
black
yeast
appear
chronic
colon
organ
cf
patient
clinic
role
fulli
understood
immunolog
reaction
host
organ
contribut
inflamm
clinic
deterior
shown
trichosporon
mycotoxinivoran
describ
chronic
colon
cf
airway
also
highli
pathogen
yeast
coupl
case
clearli
understood
factor
trigger
variabl
effect
yeast
speci
cf
lung
retrospect
analysi
data
particip
cf
center
data
collect
collabor
particip
european
cf
center
ask
provid
retrospect
data
concern
cf
patient
fungal
examin
count
speci
detect
within
time
period
januari
decemb
due
heterogen
dataset
provid
center
describ
data
compar
detail
dataset
differ
isol
method
data
count
patient
cohort
patient
manag
get
idea
rate
colon
patient
nine
center
built
mean
patient
test
posit
select
fungal
speci
per
year
relat
mean
count
patient
per
year
center
dataset
collect
european
cf
center
differ
countri
europ
thu
analyz
overal
sampl
cf
patient
includ
retrospect
analysi
rang
particip
center
sampl
patient
sampl
patient
per
year
mean
tabl
age
distribut
quit
ident
rang
year
mean
age
year
poland
particip
center
children
hospit
explain
mean
age
year
patient
followedup
hospit
analyz
sampl
origin
respiratori
tract
tabl
particip
center
perform
homogen
respiratori
sampl
use
mucolyt
agent
cultur
includ
mycolog
cultur
media
detect
yeast
mold
use
scedosporium
select
medium
eg
scesel
agar
mention
laboratori
tabl
incub
time
variabl
day
identif
tool
mainli
matrixassist
laser
desorpt
ioniz
timeofflight
malditof
mass
spectrometri
yeast
morpholog
macroscop
microscop
criteria
mold
follow
doubt
case
sequenc
analysi
intern
transcrib
spacer
region
ribosom
rna
gene
mostli
mean
sampl
cf
patient
cultur
posit
fungi
yeast
andor
mold
highlight
import
mycolog
examin
sampl
candida
albican
preval
yeast
everi
center
rang
mean
lower
divers
frequenc
candida
speci
detect
center
detail
see
tabl
yeastlik
fungi
eg
exophiala
dermatitidi
report
center
preval
rate
rang
colon
patient
mean
cultur
trichosporon
speci
includ
potenti
cf
pathogen
speci
trichosporon
mycotoxinivoran
report
rare
center
mean
main
genu
cultur
filament
fungi
aspergillu
domin
aspergillu
fumigatu
center
rang
mean
differ
fumigatu
particip
children
hospit
mean
posit
patient
per
year
tabl
concern
scedosporium
lomentospora
speci
also
geograph
variat
distribut
mean
percentag
posit
patient
differ
itali
czech
republ
center
major
preval
rate
speci
patient
colon
respiratori
tract
rasamsonia
geosmithia
argillacea
rare
seen
studi
tabl
limit
survey
heterogen
dataset
particip
center
explain
differ
isol
method
data
count
patient
cohort
patient
manag
even
divers
studi
period
particip
center
well
climat
featur
center
probabl
influenc
result
data
shown
one
cf
center
region
countri
possibl
repres
whole
countri
everi
particip
laboratori
studi
use
mucolyt
pretreat
respiratori
sampl
cf
patient
benefit
highlight
masoudlandgraf
et
al
show
higher
cultiv
rate
rare
fungi
microbiolog
laboratori
use
mycolog
cultur
media
detect
yeast
mold
impact
media
shown
differ
studi
particularli
cf
patient
faster
growth
associ
bacteria
often
mask
presenc
fungi
slowli
grow
therefor
use
mycolog
cultur
media
mandatori
tabl
fungal
epidemiolog
cystic
fibrosi
demograph
characterist
popul
studi
detect
fungi
respiratori
secret
cf
patient
cfrelat
fungal
speci
even
specif
media
shown
benefit
diagnosi
particularli
fumigatu
present
sampl
exampl
scesel
agar
enhanc
cultiv
rate
scedosporiumlomentospora
speci
erythritolchloramphenicol
agar
eca
medium
exophiala
spp
nevertheless
must
kept
mind
clinic
set
use
specif
media
associ
higher
cost
laboratori
timeconsum
besid
improv
isol
techniqu
knowledg
fungal
pathogen
mandatori
laboratori
know
limit
skill
especi
special
diagnost
question
eg
colon
rare
bacteria
filament
fungi
util
assist
special
laboratori
field
vitro
antifung
suscept
test
necessari
filament
fungi
detect
done
refer
center
laboratori
familiar
retrospect
studi
saw
great
variat
fungal
divers
quantiti
center
show
uniqu
profil
local
climat
region
biocenosi
even
differ
hygien
manag
ward
outpati
center
clinic
crosssect
analysi
european
epidemiolog
registri
cystic
fibrosi
posit
sputum
cultur
aspergillu
spp
candida
spp
associ
lower
forc
expiratori
volum
one
second
age
declin
found
singlecent
studi
uk
assum
ecolog
nich
candida
spp
respiratori
tract
due
recurr
antibiot
treatment
cours
bacteri
pathogen
eg
pseudomona
spp
nonfer
rod
corticosteroid
treatment
final
consequ
bacteri
lung
deterior
antibiot
treatment
recoveri
yeast
sputum
sampl
higher
patient
lower
studi
norway
shown
children
cf
highest
preval
c
albican
especi
treat
amoxicillin
azithromycin
thirdgener
cephalosporin
among
candida
speci
preval
rate
germani
differ
c
albican
candida
dubliniensi
candida
glabrata
candida
parapsilosi
candida
lusitania
candida
krusei
austria
found
c
albican
follow
c
dubliniensi
c
parapsilosi
c
glabrata
c
lusitania
c
krusei
retrospect
studi
south
itali
preval
rate
c
albican
follow
c
glabrata
cultur
molecular
approach
detect
fungal
speci
cf
patient
northern
ireland
cultiv
rate
c
albican
c
dubliniensi
wherea
c
parapsilosi
c
glabrata
data
set
mainli
cultur
fungal
speci
respiratori
sampl
candida
spp
major
c
albican
alreadi
seen
studi
c
dubliniensi
c
parapsilosi
c
glabrata
follow
wide
variat
respect
frequenc
one
center
anoth
tabl
despit
widespread
use
azol
antifung
could
detect
rise
count
c
glabrata
c
krusei
may
select
azol
treatment
reduc
suscept
mention
fumigatu
main
clinic
relev
filament
fungu
cf
patient
may
respons
variou
diseas
includ
asthma
bronchiti
aspergilloma
may
also
caus
invas
pulmonari
infect
immunocompromis
patient
accord
previou
publish
data
preval
rate
rang
recent
studi
found
singl
center
europ
colon
rate
germani
austria
uk
franc
itali
northern
ireland
wide
rang
colon
rate
also
seen
set
rate
differ
posit
patient
mean
tabl
rate
correl
colon
rate
c
albican
may
support
hypothesi
colon
statu
depend
diagnost
geographicclim
differ
differ
antifung
regimen
concern
major
clinic
manifest
abpa
fumigatu
bronchiti
data
ecf
show
age
depend
young
childhood
increas
adolesc
scedosporium
lomentospora
speci
patient
cf
preval
rate
multicent
prospect
studi
germani
vari
despit
use
select
cultur
medium
scesel
european
countri
report
preval
rate
scedosporium
sp
northern
ireland
austria
lomentospora
sp
franc
franc
geograph
discrep
depend
humanimpact
area
speci
clearli
shown
region
variat
epidemiolog
also
seen
analysi
preval
rate
differ
mean
particip
center
tabl
black
yeast
exophiala
dermatitidi
one
fungi
differ
cultiv
method
especi
time
cultur
day
use
select
medium
may
influenc
detect
rate
despit
found
europ
differ
publish
frequenc
sweden
northern
ireland
germani
austria
franc
data
retrospect
analysi
show
colon
rate
mean
tabl
trichosporon
spp
data
concern
epidemiolog
mycotoxinivoran
scarc
first
fulmin
report
case
cf
patient
publish
german
studi
posit
patient
rate
kept
stabl
period
northern
ireland
rate
trichosporon
sp
survey
rare
mycotoxinivoran
detect
emerg
count
observ
role
filament
fungu
often
misidentifi
penicillium
sp
paecilomyc
sp
still
unclear
rare
fungu
cultiv
cf
patient
usual
acut
clinic
deterior
observ
publish
data
preval
rate
vari
germani
austria
analysi
cf
center
speci
rare
found
center
sever
fungal
speci
identifi
respiratori
tract
cf
patient
particip
center
nonfumigatu
aspergillu
speci
paecilomyc
sp
fusarium
sp
cryptococcu
sp
etc
speci
clinic
relev
singl
case
gener
view
current
knowledg
cfrelat
pathogen
suspicion
epidemiolog
aris
rare
speci
great
variabl
one
center
anoth
detect
fungal
speci
respect
frequenc
may
due
differ
popul
followedup
center
children
adult
procedur
use
mycolog
examin
mention
climat
differ
differ
hygien
manag
nevertheless
one
may
also
consid
influenc
cftr
genotyp
due
heterogen
dataset
howev
conclud
correl
cftr
mutat
specif
risk
fungal
infect
data
european
cystic
fibrosi
societi
patient
registri
european
cf
patient
shown
larg
major
mutat
nevertheless
distribut
frequenc
mutat
within
cftr
gene
highli
variabl
alter
cftr
function
correl
infect
varieti
respiratori
pathogen
alreadi
shown
patient
residu
cftr
function
infect
p
aeruginosa
fumigatu
reduc
clearanc
aspergillu
spore
cf
airway
emphas
relat
cftr
mutat
fungal
infect
treatment
ivacaftor
patient
mutat
reduct
aspergillu
colon
rate
observ
new
cftr
modul
probabl
new
epidemiolog
short
time
studi
urgent
need
identifi
cf
patient
risk
fungal
infect
publish
data
concern
epidemiolog
clinic
relev
fungal
speci
rare
tri
give
short
summari
publish
data
european
countri
show
local
data
differ
european
cf
center
mention
heterogen
diagnost
treatment
environ
hygien
manag
cf
patient
clinic
laboratori
influenc
detect
occurr
fungal
speci
nevertheless
sampl
cf
patient
includ
retrospect
analysi
fungi
identifi
cfspecial
clinic
know
respect
frequenc
occurr
fungal
speci
might
lead
deeper
knowledg
clinic
impact
fungal
speci
improv
diagnost
treatment
option
cf
patient
correl
cftr
genotyp
bacteri
colon
fungal
speci
colon
airway
help
us
identifi
rapidli
patient
high
risk
suffer
allerg
diseas
invas
fungal
infect
